Pathology - Peter MacCallum Cancer Centre
|The Peter MacCallum Cancer Centre Pathology Department is committed to conducting all of its activities to the highest standards of quality. This commitment to quality will ensure:|
• Our clients have access to up to date laboratory services which are efficient, effective, accurate and timely.
• Our staff have continuing professional development and a safe working environment.
• Our organisation will continuously improve provision of services to our clients.
|The department encompasses most pathology subspecialties with particular expertise in anatomical pathology (6 staff specialists; 4 registrars) and haematopathology (3 staff specialists; 3 registrars). In addition to service provision to cancer patients the Pathology Department aims to accelerate the uptake of personalised medicine in cancer treatment using molecular testing. Thus, we have focused on translational pathology research and foster close relationships with our oncologists, surgeons and haematologists with strong links to other translational laboratories within and outside Peter Mac.|
|The genomic era has brought a paradigm shift to laboratory medicine such that tumours require molecular characterisation for accurate prognostic assessment and appropriate treatment stratification. The Molecular Pathology Research laboratory prides itself on being at the cutting edge of this exciting new era, introducing novel testing technologies and transferring such tests into the clinical environment. We oversee the platform selection and the design, introduction and accreditation of such new tests. |
Our laboratory also performs basic and translational research in three principle areas - the effect of angiogenesis and microenvironmental factors (particularly hypoxia) on tumour behaviour; the role of epigenetic change in the predisposition to cancer, and the identification and use of genetic and epigenetic markers capable of predicting responses to conventional and novel therapies.
|Manuscript in Press|
|Nadeem Shaida, Peter Chan, Helen Turley, Catherine M Jones, Suresh Kanga, Robert W Ritchie, Peter R Malone, Adrian L Harris and Stephen B Fox (2010) Nuclear localisation of factor-inhibitor hypoxia-inducible factor (FIH)-1 in prostate cancer is associated with a poor prognosis – for publication Journal of Urology. |
|Supplemental Materials - click to download >>|
|Pathology Service Provision >>|
|Pathology Service Subspecialties >>|
|Pathology Service Team >>|
|Pathology Service Studies & Research Findings >>|
|Department Strengths >>|